Caroline Austin

14PUBLICATIONS
42CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Cell and nuclear division
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Oct 23, 2026
Pharmacological correlates of topoisomerase II-directed protection against anthracycline-induced DNA damage and cardiotoxicity: a comparative evaluation of catalytic topoisomerase II inhibitors.

|Jul 23, 2026
Analysis of gene expression changes upon topobexin treatment and TOP2B-knockout in hiPSC-derived cardiomyocytes.

|May 27, 2025
Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection.

Jan Kubeš, Galina Karabanovich, Anh T Q Cong

|Apr 04, 2025
TOP2B is required for compartment strength changes upon retinoic acid treatment in SH-SY5Y cells.

Erica M Hildebrand, Ian G Cowell, Mushtaq M Khazeem

|Mar 26, 2024
Myeloperoxidase inhibition protects bone marrow mononuclear cells from DNA damage induced by the TOP2 poison anti-cancer drug etoposide.

Ian G Cowell, Caroline A Austin

|Jan 11, 2023
DNA fragility at the KMT2A/MLL locus: insights from old and new technologies.

Ian G Cowell, Caroline A Austin

Pageof 3

Frequent Collaborators

10 joint publications

Ian G Cowell

5 joint publications

Mushtaq M Khazeem

3 joint publications

Matthew Schellenberg

3 joint publications

Jan Kubeš